Agios Pharmaceuticals plans to share data from RISE UP with the Food and Drug Administration to support the approval of the sickle cell disease indication.
The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...
Study reveals self-administered, at-home hypnosis intervention reduces mean number of hot flashes, daily interference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback